Characteristics and Prevalence of ZA-Related AEs According to Bone Turnover Marker Status
| . | Alkaline Phosphatase . | Urine NTx . | ||||
|---|---|---|---|---|---|---|
| >125 U/L . | ≤125 U/L . | P . | >83 nm BCE/mm Cr . | ≤83 nm BCE/mm Cr . | P . | |
| n | 49 | 13 | 26 | 5 | ||
| Age, y | 11 (8–13) | 17.4 (15–18.3) | <.001 | 13.3 (10–15.4) | 19.3 (16–19.7) | .01 |
| ZA dose, mg/kg | 0.025 (0.025–0.025) | 0.025 (0.025–0.025) | .98 | 0.025 (0.0125–0.025) | 0.025 (0.025–0.025) | .15 |
| Hypocalcemia | 14/37 (37.8) | 0/12 (0) | .01 | 7/24 (29.2) | 0/3 (0) | .28 |
| Calcium decline, % | 11 (6.8–18.8) | 5.8 (1.6–12.2) | .06 | 7.4 (4.1–15.6) | 3.2 (0–13.8) | .29 |
| Hypophosphatemia | 11/30 (36.7) | 5/9 (55.6) | .31 | 5/17 (29.4) | 0/2 (0) | .37 |
| Phosphorus decline, % | 36.6 (23.3–48.9) | 36.6 (13.5–42.6) | .39 | 33.9 (22.5–40) | −5 (−24 to 13.5) | .05 |
| APR | 14/49 (25.6) | 7/13 (53.9) | .09 | 8/26 (30.8) | 1/5 (20) | .63 |
| . | Alkaline Phosphatase . | Urine NTx . | ||||
|---|---|---|---|---|---|---|
| >125 U/L . | ≤125 U/L . | P . | >83 nm BCE/mm Cr . | ≤83 nm BCE/mm Cr . | P . | |
| n | 49 | 13 | 26 | 5 | ||
| Age, y | 11 (8–13) | 17.4 (15–18.3) | <.001 | 13.3 (10–15.4) | 19.3 (16–19.7) | .01 |
| ZA dose, mg/kg | 0.025 (0.025–0.025) | 0.025 (0.025–0.025) | .98 | 0.025 (0.0125–0.025) | 0.025 (0.025–0.025) | .15 |
| Hypocalcemia | 14/37 (37.8) | 0/12 (0) | .01 | 7/24 (29.2) | 0/3 (0) | .28 |
| Calcium decline, % | 11 (6.8–18.8) | 5.8 (1.6–12.2) | .06 | 7.4 (4.1–15.6) | 3.2 (0–13.8) | .29 |
| Hypophosphatemia | 11/30 (36.7) | 5/9 (55.6) | .31 | 5/17 (29.4) | 0/2 (0) | .37 |
| Phosphorus decline, % | 36.6 (23.3–48.9) | 36.6 (13.5–42.6) | .39 | 33.9 (22.5–40) | −5 (−24 to 13.5) | .05 |
| APR | 14/49 (25.6) | 7/13 (53.9) | .09 | 8/26 (30.8) | 1/5 (20) | .63 |
Abbreviation: Cr, creatinine. Data are expressed as median (IQR) or number (percentage).
Characteristics and Prevalence of ZA-Related AEs According to Bone Turnover Marker Status
| . | Alkaline Phosphatase . | Urine NTx . | ||||
|---|---|---|---|---|---|---|
| >125 U/L . | ≤125 U/L . | P . | >83 nm BCE/mm Cr . | ≤83 nm BCE/mm Cr . | P . | |
| n | 49 | 13 | 26 | 5 | ||
| Age, y | 11 (8–13) | 17.4 (15–18.3) | <.001 | 13.3 (10–15.4) | 19.3 (16–19.7) | .01 |
| ZA dose, mg/kg | 0.025 (0.025–0.025) | 0.025 (0.025–0.025) | .98 | 0.025 (0.0125–0.025) | 0.025 (0.025–0.025) | .15 |
| Hypocalcemia | 14/37 (37.8) | 0/12 (0) | .01 | 7/24 (29.2) | 0/3 (0) | .28 |
| Calcium decline, % | 11 (6.8–18.8) | 5.8 (1.6–12.2) | .06 | 7.4 (4.1–15.6) | 3.2 (0–13.8) | .29 |
| Hypophosphatemia | 11/30 (36.7) | 5/9 (55.6) | .31 | 5/17 (29.4) | 0/2 (0) | .37 |
| Phosphorus decline, % | 36.6 (23.3–48.9) | 36.6 (13.5–42.6) | .39 | 33.9 (22.5–40) | −5 (−24 to 13.5) | .05 |
| APR | 14/49 (25.6) | 7/13 (53.9) | .09 | 8/26 (30.8) | 1/5 (20) | .63 |
| . | Alkaline Phosphatase . | Urine NTx . | ||||
|---|---|---|---|---|---|---|
| >125 U/L . | ≤125 U/L . | P . | >83 nm BCE/mm Cr . | ≤83 nm BCE/mm Cr . | P . | |
| n | 49 | 13 | 26 | 5 | ||
| Age, y | 11 (8–13) | 17.4 (15–18.3) | <.001 | 13.3 (10–15.4) | 19.3 (16–19.7) | .01 |
| ZA dose, mg/kg | 0.025 (0.025–0.025) | 0.025 (0.025–0.025) | .98 | 0.025 (0.0125–0.025) | 0.025 (0.025–0.025) | .15 |
| Hypocalcemia | 14/37 (37.8) | 0/12 (0) | .01 | 7/24 (29.2) | 0/3 (0) | .28 |
| Calcium decline, % | 11 (6.8–18.8) | 5.8 (1.6–12.2) | .06 | 7.4 (4.1–15.6) | 3.2 (0–13.8) | .29 |
| Hypophosphatemia | 11/30 (36.7) | 5/9 (55.6) | .31 | 5/17 (29.4) | 0/2 (0) | .37 |
| Phosphorus decline, % | 36.6 (23.3–48.9) | 36.6 (13.5–42.6) | .39 | 33.9 (22.5–40) | −5 (−24 to 13.5) | .05 |
| APR | 14/49 (25.6) | 7/13 (53.9) | .09 | 8/26 (30.8) | 1/5 (20) | .63 |
Abbreviation: Cr, creatinine. Data are expressed as median (IQR) or number (percentage).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
